May 21 (Reuters) - AstraZeneca laid out its target to deliver $80 billion in total revenue by 2030 on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Krishna Chandra Eluri)